Overview

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Status:
Recruiting

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Dapagliflozin
Semaglutide